GCN5 serves as an oncoprotein in various cancer types and upregulated expression of GCN5 has been reported to promote hepatic cancer, breast cancer, lung cancer, and colon cancer and is often associated with aggressive tumor progression and poor prognosis (61, 70). This evidence concerns the gene KAT2A and lung carcinoma.